These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 29856680)

  • 21. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
    Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pertussis vaccines: acellular versus whole cell. Perhaps a return to the past?].
    Cofré J
    Rev Chilena Infectol; 2015 Oct; 32(5):559-63. PubMed ID: 26633113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New pertussis vaccination approaches: en route to protect newborns?
    Locht C; Mielcarek N
    FEMS Immunol Med Microbiol; 2012 Nov; 66(2):121-33. PubMed ID: 22574832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pertussis vaccine for adolescents and adults].
    Perret P C
    Rev Chilena Infectol; 2006 Sep; 23(3):257-60. PubMed ID: 16896501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
    Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
    Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
    Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
    Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept.
    Gavillet BM; Mondoulet L; Dhelft V; Eberhardt CS; Auderset F; Pham HT; Petre J; Lambert PH; Benhamou PH; Siegrist CA
    Vaccine; 2015 Jul; 33(30):3450-5. PubMed ID: 26067183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pertussis: Where did we go wrong and what can we do about it?
    Locht C
    J Infect; 2016 Jul; 72 Suppl():S34-40. PubMed ID: 27161992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
    Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F
    Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pertussis: persistent pathogen, imperfect vaccines.
    Yeh SH
    Expert Rev Vaccines; 2003 Feb; 2(1):113-27. PubMed ID: 12901603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
    Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
    Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of co-purified acellular pertussis vaccines.
    Xu Y; Tan Y; Asokanathan C; Zhang S; Xing D; Wang J
    Hum Vaccin Immunother; 2015; 11(2):421-7. PubMed ID: 25610957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pertussis (Whooping Cough).
    Decker MD; Edwards KM
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S310-S320. PubMed ID: 34590129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.
    Bottero D; Gaillard ME; Errea A; Moreno G; Zurita E; Pianciola L; Rumbo M; Hozbor D
    Vaccine; 2013 Oct; 31(45):5262-8. PubMed ID: 24012570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.
    Patel SS; Wagstaff AJ
    Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.